Immunodeficient non-human animal

Patent metadata

Field	Value
Publication number	US-12342800-B2
Application number	US-202017030995-A
Country	US
Kind code	B2
Filing date	Sep 24, 2020
Priority date	Mar 17, 2017
Publication date	Jul 1, 2025
Grant date	Jul 1, 2025

Abstract

The present disclosure relates to the genetically modified non-human animals that have a disruption at the endogenous CD132 gene (e.g., CD132 knockout), and methods of use thereof

First claim

What is claimed is:

1. A genetically-modified non-human animal or a progeny thereof, whose genome comprises a disruption in the animal's endogenous CD132 gene, wherein the animal after being engrafted with human hematopoietic stem cells or peripheral blood cells is capable of developing a human immune system that has the following characteristics:
(a) the percentage of human CD45+ cells is greater than 70% of leukocytes of the animal;
(b) the percentage of human CD3+ cells is greater than 45% of leukocytes in the animal; and
(c) the percentage of human CD19+ cells is greater than 20% of leukocytes in the animal, wherein the disruption in the animal's endogenous CD132 gene comprises deletion of more than 150 nucleotides in exon 1, deletion of the entirety of intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7, intron 7, and deletion of more than 250 nucleotides in exon 8, wherein the animal is a NOD/scid mouse.

2. The animal of claim 1 , wherein the animal is homozygous with respect to the disruption of the endogenous CD132 gene.

3. The animal of claim 1 , wherein the animal does not express a functional CD132 protein or a functional interleukin-2 receptor.

4. The animal of claim 1 , wherein the animal has one or more of the following characteristics:
(a) the percentage of T cells (CD3+ cells) is less than 2% of leukocytes in the animal;
(b) the percentage of B cells (CD3−CD19+ cells) is less than 0.1% of leukocytes in the animal;
(c) the percentage of NK cells ( CD3−CD49b+ cells) is less than 2% of leukocytes in the animal;
(d) the percentage of CD4+ T cells is less than 0.5% of T cells;
(e) the percentage of CD8+ T cells is less than 0.5% of T cells;
(f) the percentage of CD3+CD4+ cells, CD3+CD8+ cells, or CD3−CD19+ cells is less than 1% of leukocytes in the animal; and
(g) the percentage of T cells, B cells, and NK cells is less than 5% of leukocytes in the animal.

5. The animal of claim 1 , wherein the animal has an enhanced engraftment capacity of exogenous cells relative to a NOD/scid mouse.

6. The animal of claim 1 , wherein the animal has one or more of the following characteristics:
(a) the animal has no functional T-cells and/or no functional B-cells;
(b) the animal exhibits reduced macrophage function relative to a NOD/scid mouse;
(c) the animal exhibits no NK cell activity; and
(d) the animal exhibits reduced dendritic function relative to a NOD/scid mouse.

7. The animal of claim 1 , wherein the animal further comprises a disruption in the animal's endogenous Beta-2-Microglobulin (B2m) gene or a disruption in the animal's endogenous Forkhead Box N1 (Foxn1) gene.

8. A method of determining effectiveness of an agent or a combination of agents for the treatment of cancer, comprising:
engrafting tumor cells to the animal of claim 1 , thereby forming one or more tumors in the animal;
administering the agent or the combination of agents to the animal; and
determining the inhibitory effects on the tumors.

9. The method of claim 8 , wherein before engrafting the tumor cells to the animal, human peripheral blood cells (hPBMC) or human hematopoietic stem cells are injected to the animal.

10. A method of producing an animal comprising a human hemato-lymphoid system, the method comprising:
engrafting a population of cells comprising human hematopoietic cells or human peripheral blood cells into the animal of claim 1 .

11. The method of claim 10 , wherein the human hemato-lymphoid system comprises human cells selected from the group consisting of hematopoietic stem cells, myeloid precursor cells, myeloid cells, dendritic cells, monocytes, granulocytes, neutrophils, mast cells, lymphocytes, and platelets.

12. The animal of claim 1 , wherein the percentage of human CD45+ cells is greater than 80% of leukocytes of the animal.

13. The animal of claim 1 , wherein the percentage of human CD3+ cells is at least 49% of leukocytes in the animal.

14. The animal of claim 1 , wherein the percentage of human CD19+ cells is greater than 25% of leukocytes in the animal.

15. The animal of claim 1 , wherein the disruption in the animal's endogenous CD132 gene consists of deletion of more than 150 nucleotides in exon 1, deletion of the entirety of intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7, intron 7, and deletion of more than 250 nucleotides in exon 8.

16. A genetically-modified, non-human animal whose genome comprises a disruption in the animal's endogenous CD132 gene, wherein the animal has one or more of the following characteristics:
(a) the percentage of T cells (CD3+ cells) is less than 2% of leukocytes in the animal;
(b) the percentage of B cells (CD3−CD19+ cells) is less than 0.1% of leukocytes in the animal;
(c) the percentage of NK cells (CD3−CD49b+ cells) is less than 2% of leukocytes in the animal;
(d) the percentage of CD4+ T cells is less than 0.5% of T cells;
(e) the percentage of CD8+ T cells is less than 0.5% of T cells;
(f) the percentage of CD3+CD4+ cells, CD3+CD8+ cells, or CD3−CD19+cells is less than 1% of leukocytes in the animal; and
(g) the percentage of T cells, B cells, and NK cells is less than 5% of leukocytes in the animal,
wherein the disruption in the animal's endogenous CD132 gene comprises
deletion of more than 150 nucleotides in exon 1,
deletion of the entirety of intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7, intron 7, and
deletion of more than 250 nucleotides in exon 8,
wherein the animal is a NOD/scid mouse.

17. The animal of claim 1 , wherein the animal undergoes irradiation before being engrafted with exogenous cells.

18. The animal of claim 1 , wherein the proportions of human leukocytes (hCD45+), human T cells (hCD3+) and human B cells (hCD19+) in leukocytes are analyzed using blood from the animal.

19. The animal of claim 1 , wherein the proportions of human leukocytes (hCD45+), human T cells (hCD3+) and human B cells (hCD19+) in leukocytes are analyzed at 10 weeks after being engrafted with exogenous cells.

20. The animal of claim 1 , wherein the disruption in the animal's endogenous CD132 gene is performed by CRISPR associated protein 9 (Cas9) with sgRNAs.

21. The animal of claim 1 , wherein the animal's genome has no additional genetic modifications other than the NOD/scid mutations and the disruption of the CD132 gene.

Assignees

• Biocytogen Pharmaceuticals Beijing Co Ltd

Inventors

• Shen Yuelei
• Bai Yang
• Zhang Meiling
• Yao Jiawei
• Huang Rui
• Guo Yanan

Classifications

• A01K67/0275

  Genetically modified vertebrates, e.g. transgenic · CPC title

• C12N2310/20

  involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

• C07K14/7155

  for interleukins [IL] · CPC title

• A61K49/0008

  Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure · CPC title

• A01K2267/0331

  Animal model for proliferative diseases · CPC title